Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AnaptysBio, Celgene In Strategic Antibody Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

AnaptysBio, Celgene In Strategic Antibody Pact

Aims to develop oncology and inflammation therapies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AnaptysBio has entered a strategic partnership with Celgene Corp. to develop novel antibodies against multiple therapeutic targets. AnaptysBio is responsible for generating novel therapeutic antibodies to oncology and inflammation-related targets using its SHM-XEL platform. Celgene will have worldwide rights to develop and commercialize any antibodies discovered under the terms of the partnership. AnaptysBio will receive an upfront payment, preclinical and clinical milestone payments, as well as royalties on sales.
 
“AnaptysBio is uniquely positioned with a state-of-the-art antibody platform and an experienced antibody development team,” said Hamza Suria, AnaptysBio’s president and chief executive officer. “We look forward to advancing novel antibody therapeutics with Celgene, in parallel with our internal pipeline programs.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters